Evaluation of Nocturnal Hypertension and Correlation With Target-Organ Damage

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by University of Athens.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
George S. Stergiou, University of Athens
ClinicalTrials.gov Identifier:
NCT01533584
First received: February 9, 2012
Last updated: September 9, 2012
Last verified: September 2012
  Purpose

The aim of this study is to evaluate nocturnal hypertension with 24-hour ambulatory blood pressure and home blood pressure (BP) measurements through a) comparison of mean BP and nocturnal dipping assessed with the two methods, b) correlation of those parameters with parameters of target-organ damage and c) comparison of the potential of the two methods to define non-dippers.


Condition
Nocturnal Hypertension

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Evaluation of Nocturnal Hypertension With 24-hour Ambulatory or Home Blood Pressure Measurement: Correlation With Target-Organ Damage

Resource links provided by NLM:


Further study details as provided by University of Athens:

Estimated Enrollment: 100
Study Start Date: March 2012
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Detailed Description:

It is well known that blood pressure (BP) exhibits diurnal variation. Nocturnal fall of BP normally exceeds 10%. Subjects with such fall of BP during sleep are classified as "dippers" and those with a nocturnal fall of BP less than 10% are classified as "non-dippers". Non-dippers are exposed to a greater cardiovascular risk. To date dipping status is defined with 24-hour ambulatory BP monitoring (ABPM). Many studies have shown that Home BP monitoring (HBPM) can be an alternative to daytime ambulatory BP monitoring and it exhibits similar correlation to markers of hypertension target-organ-damage (TOD). Nocturnal hypertension shows closer correlation with TOD, than daytime hypertension. In this study patients will be provided with a new-technology, reliable oscillometric device for HBPM, equipped with a modified algorithm, which allows scheduled automated BP measurements during sleep (Microlife WatchBP Home Nocturnal). Duplicate morning and evening BP measurements with one-minute interval will be performed by the patient sitting during seven working days. Afterwards a 24-hour ABPM will be performed, using Microlife WatchBP O3 oscillometric device, with a 20-minute interval between measurements. This order may be reversed according to the wish of the patient and devices' availability. Participants will visit site 3 times. Office blood pressure will be measured during two visits. Triplicate measurements with Microlife WatchBP Home Nocturnal will be performed at the sitting position.

TOD will be assessed with:

  • cardiac triplex (LVMI)
  • carotid triplex (ΙΜΤ)
  • pulse wave velocity.
  • Albumin/creatinine ratio measured in morning urine sample.
  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Subjects referred for high Blood Pressure, untreated or, if treated for less than 2 weeks, 4 weeks after withdrwal of treatment.

Criteria

Inclusion Criteria:

  • Mean 24-hour Systolic BP (SBP) >130 mmHg and/or Mean 24-hour Diastolic BP (DBP) >80 mmHg.
  • Patients physically and mentally capable of self-measuring BP at home.
  • Written informed consent.

Exclusion Criteria:

  • Sustained arrhythmia.
  • Pregnancy.
  • Symptomatic cardiovascular disease.
  • Any other serious illness (cardiac, renal, or malignancy).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01533584

Locations
Greece
Hypertension Center, Third Department of Medicine, University of Athens, Greece Recruiting
Athens, Greece, 11527
Contact: George S Stergiou, MD    +302107763117    gstergi@med.uoa.gr   
Principal Investigator: George S Stergiou, MD         
Hypertension Clinic, 3rd Dept. of Medicine, Evaggelismos Hospital. Recruiting
Athens, Greece, 10676
Contact: Emmanuel A Andreadis, NHS Director    00302132045149    andreadise@ath.forthnet.gr   
Principal Investigator: Emmanuel A Andreadis, NHS Director         
Sponsors and Collaborators
University of Athens
  More Information

No publications provided

Responsible Party: George S. Stergiou, Associate Professor of Medicine and Hypertension, University of Athens
ClinicalTrials.gov Identifier: NCT01533584     History of Changes
Other Study ID Numbers: NOCTURNAL TOD
Study First Received: February 9, 2012
Last Updated: September 9, 2012
Health Authority: Greece: Ethics Committee

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014